Non-Invasive Assessment of Hepatic Lipid Subspecies Matched with Non-Alcoholic Fatty Liver Disease Phenotype

Publication date: Available online 21 June 2019Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): M.L. Erickson, J.M. Haus, S.K. Malin, C.A. Flask, A.J. McCullogh, J.P. KirwanAbstractBackground and aimsNonalcoholic fatty liver disease (NAFLD) is characterized by excessive hepatic fat accumulation. Increased hepatic saturated fats and decreased hepatic polyunsaturated fats may be particularly lipotoxic, contributing to metabolic dysfunction. We compared hepatic lipid subspecies in adults with and without NAFLD, and examined links with hallmark metabolic and clinical characteristics of NAFLD.Methods and resultsNineteen adults with NAFLD (total hepatic fat:18.8 ± 0.1%) were compared to sixteen adults without NAFLD (total hepatic fat: 2.1 ± 0.01%). 1H-MRS was used to assess hepatic lipid subspecies. Methyl, allylic, methylene, and diallylic proton peaks were measured. Saturation, unsaturation, and polyunsaturation indices were calculated. Whole-body phenotyping in a subset of participants included insulin sensitivity (40 mU/m2 hyperinsulinemic-euglycemic clamps), CT-measured abdominal adipose tissue depots, exercise capacity, and serum lipid profiles. Participants with NAFLD exhibited more saturated and less unsaturated hepatic fat, accompanied by increased insulin resistance, total and visceral adiposity, triglycerides, and reduced exercise capacity compared to controls (all P
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research

Related Links:

ConclusionExperimental validation of network analysis revealed anti-diabetic effects of the plant product SGD, manifested most notably by improved serum profiles and diminished insulin resistance. These experimental results may have clinical implications.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
The identification of patients with advanced liver fibrosis secondary to non-alcoholic fatty liver disease (NAFLD) remains challenging. Using non-invasive liver fibrosis tests (NILT) in primary care may permit...
Source: BMC Gastroenterology - Category: Gastroenterology Authors: Tags: Research article Source Type: research
In this issue of Metabolism, Omori et al [1] report that dapagliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), prevents hepatic steatosis (assessed by triglyceride liver content) after 8  weeks of administration in db/db mice, a mouse model of obesity and diabetes.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research
Publication date: Available online 10 July 2019Source: Life SciencesAuthor(s): Yunxia Dong, Henglei Lu, Qiang Li, Xinming Qi, Yuanchao Li, Zean Zhang, Jing Chen, Jin RenAbstractAims(5R)-5-hydroxytriptolide (LLDT-8) is a triptolide analog with excellent capability against cancers, cerebral ischemic injury and rheumatoid arthritis. Here, we discovered its hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease (NAFLD) by ameliorating liver lipid accumulation.Main methodsMale C57BL/6J mice were fed with a high-fat/high-fructose (HFHFr) diet for 29 weeks to induce the pathological phenomena of NAFLD. T...
Source: Life Sciences - Category: Biology Source Type: research
In this study, the effects of AGE on fatty liver, insulin resistance and intestinal microbiota were compared between ddY-H mice, an insulin resistance mouse, and ddY-L mice, normal mice. Mice were fed an AGE-supplemented diet (4% w/w) for 7 weeks. The administration of AGE had no effect on the body weight and dietary intake of both types of mice. In the ddY-H mice, the serum levels of glucose and insulin were increased and glucose tolerance was impaired; however, the administration of AGE ameliorated these abnormal conditions. AGE did not have these effects in ddY-L mice. Triglyceride (TG) accumulation in the liver and fat...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
The recent epidemic in chronic liver disease is related to the burden of Non-Alcoholic Fatty Liver Disease (NAFLD), paralleling the worldwide increase of obesity. [1] NAFLD is a complex condition related to metabolic derangements in insulin resistance (IR), but in a subset of patients the liver becomes the target of multiple hits leading to Non-Alcoholic SteatoHepatitis (NASH), the histological phenotype that may progressively develop liver fibrosis, cirrhosis and possibly hepatocellular carcinoma.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
CONCLUSIONS: NAFLD was associated with rUTI in premenopausal women, independent of metabolic syndrome. Further studies are needed to confirm this association. PMID: 31280506 [PubMed - in process]
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
ConclusionsSMI level in patients with NAFLD was lower than healthy people, and patients with sarcopenia have higher occurrence risk of NAFLD, as well as its advanced stages including NASH or NAFLD-related significant fibrosis. Further well-designed prospective studies are required to strengthen the arguments.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
IFN-α-2b treatment protects against diet-induced obesity and alleviates non-alcoholic fatty liver disease in mice. Toxicol Appl Pharmacol. 2019 Jul 09;:114650 Authors: Quiroga AD, Comanzo CG, Heit Barbini FJ, Lucci A, Vera MC, Lorenzetti F, Ferretti AC, Ceballos MP, Alvarez ML, Carrillo MC Abstract IFN-α is used for inflammatory purposes, and obesity and NAFLD are strongly correlated with inflammatory processes. We wondered whether IFN-α-2b can attenuate obesity development and its associated NAFLD in mice fed high fat diet (HFD) for 10 weeks. IFN-α-2b had a robust effect on ...
Source: Toxicology and Applied Pharmacology - Category: Toxicology Authors: Tags: Toxicol Appl Pharmacol Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is a global public health concern. Its natural history, the development of non-alcoholic steatohepatitis (NASH) and fibrosis, is highly variable, prone to endogenous (e.g., genetics, microbiota) and exogenous (e.g., nutrition, alcohol, physical activity) disease modifiers, and can fluctuate over time. The complexity of its pathophysiology is reflected by the multitude of pharmacological targets in development. NASH clinical trials have provided valuable insight that is applicable to future trial design.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Review Source Type: research
More News: Alcoholism | Cardiology | Cardiovascular | Fatty Liver Disease (FLD) | Heart | Insulin | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Saturated Fat | Sports Medicine | Unsaturated fat | Urology & Nephrology